StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen r&d expenses

Research and development expenses are spending on new products and technology.

Repligen's R&D Expenses for the twelve months ending Sep 30, 2026 was $57.23M, up 10.2% year over year. For fiscal 2025 it was $54.18M, up 25.4% from the year before. Over ten years it grew 25.2% a year on average. The highest annual figure on record is $54.18M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.18M+25.4%
FY2024Dec 31, 2024$43.20M+1.1%
FY2023Dec 31, 2023$42.72M-2.8%
FY2022Dec 31, 2022$43.94M+28.2%
FY2021Dec 31, 2021$34.27M+69.8%
FY2020Dec 31, 2020$20.18M+3.8%
FY2019Dec 31, 2019$19.45M+22.9%
FY2018Dec 31, 2018$15.82M+82.4%
FY2017Dec 31, 2017$8.67M+17.9%
FY2016Dec 31, 2016$7.36M+28.1%
FY2015Dec 31, 2015$5.74M+2.3%
FY2014Dec 31, 2014$5.61M-23.6%
FY2013Dec 31, 2013$7.34M-41.4%
FY2011Mar 31, 2011$12.53M-11.5%
FY2010Mar 31, 2010$14.16M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$14.44M+1.8%
Q2 FY2026Jun 30, 2026$14.42M+3.2%
Q1 FY2026Mar 31, 2026$14.46M+19.3%
Q4 FY2025Dec 31, 2025$13.92M+19.2%
Q3 FY2025Sep 30, 2025$14.18M+46.0%
Q2 FY2025Jun 30, 2025$13.97M+32.1%
Q1 FY2025Mar 31, 2025$12.11M+7.8%
Q4 FY2024Dec 31, 2024$11.68M+13.5%
Q3 FY2024Sep 30, 2024$9.71M-8.2%
Q2 FY2024Jun 30, 2024$10.58M+9.0%
Q1 FY2024Mar 31, 2024$11.24M-7.5%
Q4 FY2023Dec 31, 2023$10.29M-7.5%
Q3 FY2023Sep 30, 2023$10.58M+3.4%
Q2 FY2023Jun 30, 2023$9.71M-7.0%
Q1 FY2023Mar 31, 2023$12.15M-0.0%
Q4 FY2022Dec 31, 2022$11.11M+21.9%
Q3 FY2022Sep 30, 2022$10.23M+11.7%
Q2 FY2022Jun 30, 2022$10.44M+24.4%
Q1 FY2022Mar 31, 2022$12.16M+59.7%
Q4 FY2021Dec 31, 2021$9.12M+35.7%
Q3 FY2021Sep 30, 2021$9.15M+107.0%
Q2 FY2021Jun 30, 2021$8.39M+93.5%
Q1 FY2021Mar 31, 2021$7.61M+61.9%
Q4 FY2020Dec 31, 2020$6.72M+30.0%
Q3 FY2020Sep 30, 2020$4.42M-18.5%
Q2 FY2020Jun 30, 2020$4.34M-17.1%
Q1 FY2020Mar 31, 2020$4.70M+29.9%
Q4 FY2019Dec 31, 2019$5.17M+64.1%
Q3 FY2019Sep 30, 2019$5.43M+50.7%
Q2 FY2019Jun 30, 2019$5.23M-9.5%
Q1 FY2019Mar 31, 2019$3.62M+10.1%
Q4 FY2018Dec 31, 2018$3.15M+2.7%
Q3 FY2018Sep 30, 2018$3.60M+80.0%
Q2 FY2018Jun 30, 2018$5.78M+210.8%
Q1 FY2018Mar 31, 2018$3.29M+88.7%
Q4 FY2017Dec 31, 2017$3.07M+50.4%
Q3 FY2017Sep 30, 2017$2.00M–
Q2 FY2017Jun 30, 2017$1.86M–
Q1 FY2017Mar 31, 2017$1.74M–
Q4 FY2016Dec 31, 2016$2.04M–

More Repligen figures

See a number that looks wrong?